---
title: "Unique Friend | Yuemi Tech Validates Specialty-Disease Pharma Marketing Collab Platform — Commercial Rollout"
author: "Unique Research"
sourcePublication: "Unique Research (FFCAP English library)"
originalPublishedAt: "2022-12-05T23:46:53+08:00"
canonical: "https://ffcap.cn/en/research/20221205a09s4e00"
source: "https://ffcap.cn/en/research/20221205a09s4e00"
language: "en"
cnSourceUrl: "https://view.inews.qq.com/a/20221205A09S4E00"
---

# Unique Friend | Yuemi Tech Validates Specialty-Disease Pharma Marketing Collab Platform — Commercial Rollout

_Unique Research · Unique Friend / Event · December 5, 2022_

Interview with **Qiao Minghui**, founder & CEO of **Yuemi Tech (悦米科技)** — data-driven pharma/device digital-marketing solutions (private-domain doctor–patient, integrated care, data/biz mid-platforms). Shanghai “专精特新”; dozens of software copyrights; national tech SME + high-tech firm.

**Stack:** MedChat-based smart mid-platform; MedEvent scene systems; WeChat private-domain ops bridging online/offline; open platform integrating academic libraries, societies, DSP/DMP for closed-loop digital marketing. 7 years: 150+ top domestic/foreign pharma-device clients; 500+ innovative-drug pipelines. Clients: Roche, AbbVie, Abbott, J&J, Medtronic; HengRui, Hansoh, Yangtze River, CTTQ; Fudan-Zhangjiang, Zai Lab, Henlius. 2022 revenue growth expected >80%. Prior investors: Kaiyu Group, Sinopharm CICC; Aug 2021 multi-million A round. New round open — **Unique Capital as FA**. Team >150 (60%+ from pharma marketing/enterprise services; core 15y+ tenure). CDP suite: MedLink + MedData + MedBI for precise academic promotion.

**2022 milestone:** MedOS specialty-disease pharma marketing collaboration platform validated and entering commercial promotion — patient-centric, integrating Sinopharm strategic-shareholder resources around clinical pathways: recruit → educate → follow-up → manage; multi-vendor products/services; tens of millions RMB into disease KG, ops systems, data-driven platforms. Cases: doctor–patient–enterprise triad platform; MedLink full-funnel tracking for sales lift. 2023: deepen channel/doctor/patient pillars; expand innovative-drug + C-end; evolve from B2B systems to full-course platform linking pharma, doctors, patients, innovative payment, DTP pharmacies. Policy (VBP, insurance cost control, two-invoice) + AI/big data push digital marketing from support act to lead; MNCs/innovators may leap in 2–3 years, broader peers in ~5. Pharma firms already allocate ~10–30% budgets to digital channels post-COVID.

— END —

---

Editorial English edition published on UniqueCapital: https://ffcap.cn/en/research/20221205a09s4e00
On-site reading page: https://ffcap.cn/en/research/20221205a09s4e00